The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma

Proteasome inhibitors, such as bortezomib, are first-line therapy against multiple myeloma (MM). Unfortunately, patients frequently become refractory to this treatment. The transcription factor NRF1 has been proposed to initiate an adaptation program that regulates proteasome levels. In the context...

Descripción completa

Detalles Bibliográficos
Autores principales: Op, Mélanie, Ribeiro, Sérgio T., Chavarria, Claire, De Gassart, Aude, Zaffalon, Léa, Martinon, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120136/
https://www.ncbi.nlm.nih.gov/pubmed/35589686
http://dx.doi.org/10.1038/s41419-022-04925-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120136/
https://www.ncbi.nlm.nih.gov/pubmed/35589686
http://dx.doi.org/10.1038/s41419-022-04925-3

Ejemplares similares